Abstract:Objective: To investigate the diagnostic value of serum pepsinogen (PG) Ⅰ/PGⅡ combined with tumor markers for Helicobacter pylori ( Hp)-positive early-stage gastric cancer. Methods: A retrospective study was conducted with the clinical data of 109 patients with gastric cancer (the gastric cancer group), 115 patients with chronic atrophic gastritis (the benign group), 112 cases of low-grade intraepithelial neoplasia (the low grade group), 109 cases of high-grade intraepithelial neoplasia (the high grade group), and 104 healthy subjects who underwent the relevant screening tests as part of their general physical examination (the healthy group). All the subjects were admitted to or received care at our hospital between May 2018 and April 2021. The levels of serum PGⅠ, PGⅡ, carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), and carbohydrate antigen 724 (CA724), and Hp infection status were examined. The findings for these indicators were compared among the groups, and the differences in serum indicators in Hp-positive and Hp-negative patients were compared. The diagnostic value of serum PGⅠ/PGⅡ combined with tumor markers for Hp-positive early-stage gastric cancer was assessed with receiver operating characteristic (ROC) curve. Results: The serum levels of PGⅠ and PGⅠ/PGⅡ decreased in successive order in the healthy group, the benign group, the low grade group, the high grade group, and the gastric cancer group ( P<0.05). The serum levels of PGⅡ, CEA, CA199, and CA724 in the gastric cancer group, the high grade group, and the low grade group were all higher than those in the healthy group and the benign group ( P<0.05). The Hp-positive rates of the gastric cancer group, the high grade group, the low grade group and the benign group were higher than that of the healthy group ( P<0.01). The levels of serum PGⅠ, PGⅡ, CEA, CA199, and CA724 of the Hp-positive subjects of the healthy group, the benign group, the low grade group, the high grade group, and the gastric cancer group were higher than those of the Hp-negative subjects ( P<0.05), while their PGⅠ/PGⅡ levels were always lower than those of the Hp-negative persons ( P<0.05). The specificity and area under the curve ( AUC) of serum PGⅠ/PGⅡ, CEA, CA199, and CA724 in the combined diagnosis of Hp-positive early-stage gastric cancer were higher than those of each indicator used alone in diagnosis ( P<0.05). In the gastric cancer group, the proportion of patients with PGⅠ/PGⅡ>2.32 was lower in the Hp-positive patients than that in the Hp-negative patients ( P<0.05), while the proportions of patients with CEA>66.99 ng/mL, CA199>110.35 U/mL, and CA724>44.20 U/mL were higher in the Hp-positive patients than those in the Hp-negative patients ( P<0.05). Conclusion: Testing PGⅠ/PGⅡ in combination with CEA, CA199, and CA724 results in better diagnostic value for Hp-positive early-stage gastric cancer.

Clinical significance of serum markers reflecting gastric function and H. pylori infection in colorectal cancer

Significance of Elevated Serum PGI and PG II Levels in Patients with Gastric Cancer after Total Gastrectomy

The Potential for Serum P53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer

Helicobacter pylori infection, H19 and LINC00152 expression in serum and risk of gastric cancer in a Chinese population

Effect of Gastrin G-17 Combined with Pepsinogen PGI and PGII on the Early Screening of Gastric Cancer in the Department of Gastroenterology

Abstract C13: Population-based Evaluation of Serum Pepsinogen, Anti-H. Pylori IgG Antibody and Gastrin-17 Tests for Gastric Cancer Screening

Prognostic role of C-reactive protein in gastric cancer: a meta-analysis.

The role of gastrin 17 and pepsinogen I:pepsinogen II ratio in pathological diagnosis and endoscopic selection in gastritis patients

[The Associations of Serum Gastrin Level with Helicobacter Pylori Infection].

[Diagnostic Value of Serum Pepsinogen Ⅰ/Pepsinogen Ⅱ Combined with Tumor Markers for Helicobacter pylori-Positive Early-Stage Gastric Cancer]

Relationship between serum PGI ,PGⅡ,CA50 and CA724 expression levels and short?term prognosis in gastric cancer at different stages

Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions

Association of <i>Helicobacter pylori</i> infection with colorectal polyps and malignancy in China

Correlation Analysis of Serum Pepsinogen, Interleukin, and TNF-α with Hp Infection in Patients with Gastric Cancer: A Randomized Parallel Controlled Clinical Study

Serum Anti-Helicobacter Pylori Immunoglobulin G Titer Correlates with Grade of Histological Gastritis, Mucosal Bacterial Density, and Levels of Serum Biomarkers.

Influence of Helicobacter pylori Infection on Diagnostic Performance of Serum Pepsinogens

Clinical Value of Pepsinogen in the Screening, Prevention, and Diagnosis of Gastric Cancer

Serum pepsinogen II levels are doubled with <i>Helicobacter pylori</i> infection in an asymptomatic population of 40,383 Chinese subjects

Polymorphisms in Pepsinogen C and miRNA Genes Associate with High Serum Pepsinogen II in Gastric Cancer Patients

Temporal Changes in Serum Biomarkers and Risk for Progression of Gastric Precancerous Lesions: a Longitudinal Study.

Clinical Significance in Combined Detection of Serum Pepsinogen I, Pepsinogen II and Carbohydrate Antigen 242 in Gastric Cancer.